See more : Boryung Corporation (003850.KS) Income Statement Analysis – Financial Results
Complete financial analysis of CStone Pharmaceuticals (CSPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CStone Pharmaceuticals, a leading company in the Biotechnology industry within the Healthcare sector.
- Red Mountain Mining Limited (RMX.AX) Income Statement Analysis – Financial Results
- Nord Precious Metals Mining Inc. (NTH.V) Income Statement Analysis – Financial Results
- Tombstone Exploration Corporation (TMBXF) Income Statement Analysis – Financial Results
- EDP – Energias de Portugal, S.A. (ELCPF) Income Statement Analysis – Financial Results
- IDOM Inc. (7599.T) Income Statement Analysis – Financial Results
CStone Pharmaceuticals (CSPHF)
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 463.84M | 481.36M | 243.72M | 1.04B | 0.00 | 12.55M | 10.30M | 0.00 |
| Cost of Revenue | 159.55M | 202.99M | 106.83M | 241.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 304.30M | 278.38M | 136.89M | 797.41M | 0.00 | 12.55M | 10.30M | 0.00 |
| Gross Profit Ratio | 65.60% | 57.83% | 56.17% | 76.76% | 0.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 527.80M | 614.16M | 1.30B | 1.40B | 1.40B | 850.20M | 213.44M | 247.12M |
| General & Administrative | 48.72M | 63.18M | 109.20M | 86.73M | 86.23M | 81.38M | 39.34M | 15.05M |
| Selling & Marketing | 199.35M | 327.30M | 363.79M | 142.15M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 248.07M | 390.48M | 472.99M | 228.88M | 86.23M | 81.38M | 39.34M | 15.05M |
| Other Expenses | -471.57M | 177.25M | 152.42M | 228.27M | 256.21M | 127.52M | 146.00K | 88.00K |
| Operating Expenses | 304.30M | 1.18B | 1.93B | 1.86B | 1.74B | 1.06B | 242.48M | 262.17M |
| Cost & Expenses | 1.07B | 1.38B | 2.04B | 2.10B | 1.74B | 1.06B | 242.48M | 262.17M |
| Interest Income | 24.89M | 9.67M | 9.80M | 24.16M | 67.29M | 7.95M | 3.51M | 99.00K |
| Interest Expense | 11.82M | 8.48M | 2.24M | 1.32M | 303.00K | 0.00 | 60.00K | 240.00K |
| Depreciation & Amortization | 58.19M | 44.54M | 22.66M | 14.80M | 6.40M | 5.10M | 811.00K | 67.00K |
| EBITDA | -297.23M | -849.66M | -1.90B | -1.20B | -1.73B | -1.02B | -241.67M | -262.10M |
| EBITDA Ratio | -64.08% | -163.65% | -750.91% | -116.22% | 0.00% | -7,301.53% | -2,598.27% | 0.00% |
| Operating Income | -534.61M | -832.27M | -1.85B | -1.22B | -1.56B | -1.06B | -242.48M | -262.17M |
| Operating Income Ratio | -115.26% | -172.90% | -760.20% | -117.64% | 0.00% | -8,439.02% | -2,354.14% | 0.00% |
| Total Other Income/Expenses | 167.37M | 9.47M | -90.66M | -129.07M | -571.34M | -764.49M | -100.07M | 9.13M |
| Income Before Tax | -367.23M | -902.68M | -1.92B | -1.22B | -2.31B | -1.79B | -342.55M | -253.04M |
| Income Before Tax Ratio | -79.17% | -187.53% | -787.84% | -117.54% | 0.00% | -14,287.88% | -3,325.70% | 0.00% |
| Income Tax Expense | 0.00 | 61.93M | 67.35M | -1.10M | 748.39M | -734.03M | -59.61M | 7.84M |
| Net Income | -367.23M | -964.61M | -1.99B | -1.22B | -3.06B | -1.75B | -308.90M | -246.09M |
| Net Income Ratio | -79.17% | -200.39% | -815.47% | -117.43% | 0.00% | -13,906.59% | -2,999.07% | 0.00% |
| EPS | -0.29 | -0.82 | -1.71 | -1.17 | -3.53 | -1.79 | -0.32 | -0.25 |
| EPS Diluted | -0.29 | -0.82 | -1.71 | -1.17 | -3.53 | -1.77 | -0.31 | -0.25 |
| Weighted Avg Shares Out | 1.26B | 1.17B | 1.16B | 1.04B | 865.58M | 973.32M | 973.32M | 984.05M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.17B | 1.17B | 1.05B | 866.73M | 984.05M | 984.05M | 984.05M |
Source: https://incomestatements.info
Category: Stock Reports